Thus, the combination of anti‐inflammatory and anti‐triglyceridemic activity with an ApoC3 inhibition strategy may prove superior to any prior therapy that has been trialed for PAD, and the effects of ApoC3 inhibition are likely to impact on coronary artery disease (CAD)‐related events in people with PAD and CAD as well. This evidence concerns the gene APOC3 and coronary artery disorder.